Evercore ISI Group maintains Doximity at In-Line, lowers price target to $33 from $35

Evercore ISI Group kept Doximity's rating at In-Line but reduced its price target from $35 to $33, a 5.7% cut. The new target is close to Doximity's Nov 5 closing price of $33.18.

Original reporting
Published Nov 6, 2026, 2:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 2:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Evercore ISI Group maintains Doximity at In-Line, lowers price target to $33 from $35 — source image
Decision brief

The 30-second read

Low
01

Why it matters

The downgrade may trigger modest sell‑offs, but the effect is limited given the small change and lack of broader catalyst.

02

Market read

A modest analyst target cut with limited immediate market impact; primarily relevant to traders with short positions in DOC.

03

What to watch

Potential upcoming product launches or partnership announcements that could offset the target reduction.

Relevance 6/10Novelty 5/10Timing: today

Background

Evercore ISI provides equity research coverage; price target adjustments are routine but can influence short‑term trading.

Market effects

Minimal impact on the broader health‑tech sector; only a single analyst view change.

U.S. market only; no regional ripple.

Low; Doximity is a niche professional network.

Counterpoint

Some investors may view the target cut as an overreaction and see buying opportunity if fundamentals remain solid.

Key entities

  • Evercore ISI Group

    Equity research analyst firm issuing the target change.

  • Doximity Inc.

    Professional network for physicians, ticker DOC.

Related articles

Med

Doximity: 3 Key Takeaways for Long-Term Investors

Doximity updated its full-year revenue guidance to $678M-$683M, citing steady demand and pricing discipline. The company highlights operating efficiency and AI investments as key drivers. According to CFO Matthew Sonefeldt, these factors support continued growth amid technological shifts.

$DOCSMedAI 8/10

DOCS Q3 CY2026 deep dive: AI-driven product expansion meets margin compression

Doximity reported Q3 CY2026 revenue of $174.5M, beating estimates by 2%, with adjusted EPS in line. Adjusted EBITDA exceeded expectations by 9.1%, but operating margin fell to 25.2% from 37.8% YoY. The company raised full-year revenue guidance to $680.5M and maintained EBITDA guidance at $321M. AI product adoption surged, with 16 of the top 20 pharma companies using AI Search. New health system clients and partnerships were added, driving growth.

$DOCSMedAI 8/10

Doximity Q2 Earnings Call Highlights

Doximity (DOCS) reported Q2 earnings, raising fiscal 2027 revenue guidance to $678M-$683M. AI Search revenue is expected to ramp gradually. Health system clients grew to 190, including 10 of the top 20 hospitals. Non-GAAP EPS was $0.36, with $713M in cash. Management discussed AI monetization and adoption challenges.

$DOCSMedAI 8/10

Doximity Earnings Call Highlights AI Growth and Guidance

Doximity (DOCS) reported Q2 revenue of $175M (+4% YoY), beating expectations. Adjusted EBITDA was $89M (51% margin), exceeding guidance. AI initiatives drove growth, with expanded health-system adoption and improved AI economics. Revenue guidance raised to $678M-$683M for 2027. Challenges include modest growth, margin pressure, and AI-search return uncertainty.